Xilio Therapeutics, Inc. (XLO)

Market Cap	49.36M +32.4%
Revenue (ttm)	53.48M +476.7%
Net Income	-31.30M
EPS	-5.41
Shares Out	5.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,469
Open	8.40
Previous Close	8.58
Day's Range	8.17 - 8.60
52-Week Range	6.47 - 16.10
Beta	-0.13
Analysts	Strong Buy
Price Target	20.00 (+141.55%)
Earnings Date	May 12, 2026

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Financial Performance

In 2025, Xilio Therapeutics's revenue was $43.77 million, an increase of 589.88% compared to the previous year's $6.34 million. Losses were -$35.04 million, -39.84% less than in 2024.

Analyst Summary

According to one analyst, the rating for XLO stock is "Strong Buy" and the 12-month stock price target is $20.0.

Price Target

$20.0

(141.55% upside)

Analyst Consensus: Strong Buy